Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission

Transitioning from IV to SC vedolizumab in patients with IBD in remission showed comparable effectiveness in maintaining disease remission and persistence. Patients on IV are more likely to need drug intensification during follow-up.

Authors

Institutions

Publication Details

Journal
Revista Española de Enfermedades Digestivas
Published
2025-01-01
DOI
https://doi.org/10.17235/reed.2025.11525/2025
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission

Jordi Guardiola, G E Rodríguez, Carles Suria, Erika Alfambra et al.
Revista Española de Enfermedades Digestivas
Inflammatory Bowel Disease
article

Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission

Jordi Guardiola, G E Rodríguez, Carles Suria, Erika Alfambra, Iván Guerra, Ángel Ponferrada, S Marín Pedrosa, José María Huguet, Antonio Maria Caballero-Mateos, Noemí Manceñido, Marisa Iborra, Francisco Mesonero, Pere Antoni Borràs, Berta Caballol, Fiorella Cañete, Francisco López Romero-Salazar, Ana Gutiérrez, Manuel Barreiro‐de Acosta, Beatriz Gros, Pilar Soto Escribano, Laura García, Jesús Castro Poceiro, Inmaculada Alonso Abreu, Iago Rodríguez–Lago, Beatriz Castro Senosain, Yamile Zabana, Rubén Alvarado, Federico Argüelles‐Arias, Eduard Brunet‐Mas, J M Benítez, Lucía Madero Velázquez, Eva Iglesias Flores, Judit Orobitg
article en

Abstract

Transitioning from IV to SC vedolizumab in patients with IBD in remission showed comparable effectiveness in maintaining disease remission and persistence. Patients on IV are more likely to need drug intensification during follow-up.

Revista Española de Enfermedades Digestivas
Hospital Universitario de Canarias (ES), Bellvitge University Hospital (ES), Hospital Universitari i Politècnic La Fe (ES), Hospital Universitario Nuestra Señora de Candelaria (ES), Hospital Universitario Virgen Macarena (ES), Hospital Clínico Universitario de Valencia (ES), Complejo Hospitalario Universitario de Santiago (ES), Marqués de Valdecilla University Hospital (ES), Hospital Universitario Fundación Alcorcón (ES), Hospital Universitario 12 De Octubre (ES), Instituto de Investigación Marqués de Valdecilla (ES), Instituto de Investigación Biosanitaria de Granada (ES), Hospital Clínic de Barcelona (ES), Corporació Sanitària Parc Taulí (ES), Hospital de Galdakao (ES), Hospital Universitario Reina Sofía (ES), Hospital General Universitario De Valencia (ES), Mútua Terrassa (ES), Hospital de Sant Joan Despí Moisès Broggi (ES), Hospital Clínico Universitario Lozano Blesa (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Hospital Universitario de Fuenlabrada (ES), Hospital Universitari Germans Trias i Pujol (ES), Hospital Universitario Infanta Sofía (ES), Hospital Universitario Ramón y Cajal (ES), Hospital Universitario Infanta Leonor (ES)
Openalex Percentile: Top 71%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.